Functional Analysis of GATA4 Complex, a Cardiac Hypertrophy-response Transcriptional Factor, Using a Proteomics Approach

• Published in: YAKUGAKU ZASSHI Vol. 136; no. 2; pp. 151 - 156
• Main Authors: Sunagawa, Yoichi, Katanasaka, Yasufumi, Wada, Hiromichi, Hasegawa, Koji, Morimoto, Tatsuya
• Format: Journal Article
• Language: Japanese; English
• Published: Japan The Pharmaceutical Society of Japan 01.02.2016
• Subjects: Cardiomegaly - drug therapy; Cardiomegaly - genetics; Cyclin-Dependent Kinase 9; GATA4; GATA4 Transcription Factor - isolation & purification; GATA4 Transcription Factor - physiology; heart failure; Histone Acetyltransferases; Humans; hypertrophy; Molecular Targeted Therapy; Multiprotein Complexes; p300; p300-CBP Transcription Factors; Protein Binding; Proteomics; Retinoblastoma-Binding Protein 4; Signal Transduction - genetics; Signal Transduction - physiology
• ISSN: 0031-6903; 1347-5231
• DOI: 10.1248/yakushi.15-00226-2

Various stresses on the heart, such as myocardial infarction and hemodynamic overload, activate the sympathetic nervous system and the renin-angiotensin system, ultimately reach the nuclei of cardiomyocytes, and change the pattern of gene expression associated with cardiac hypertrophy. Although present pharmacological therapy for heart failure targets such extracellular molecules, mortality due to heart failure is still high. A zinc finger protein, GATA4, is one of the hypertrophy-responsive transcription factors, forms a functional protein complex with an intrinsic histone acetyltransferase, p300, and regulates pathological cardiac hypertrophy. Disruption of this complex results in the inhibition of cardiac hypertrophy and heart failure in vivo. To establish a more effective therapy for heart failure, we have been analyzing a common nuclear pathway within cardiomyocytes. We identified 73 GATA4 binding proteins by tandem-affinity purification and mass spectrometric analysis. Noble GATA4 binding partners, such as cyclin-dependent kinase-9 (Cdk9: the core factor of positive transcription elongation factor b) and retinoblastoma-association protein 48/46 (RbAp48/46: the co-repressor complexes containing HDAC1/2), regulate the p300/GATA4-mediated signaling pathway and hypertrophic responses. Further analysis of p300/GATA4 complex is expected to identify target molecules for heart failure therapy.